- Irbesartan in the treatment of patients with diabetes mellitus and renal dysfunction Irbesartan in the treatment of patients with diabetes mellitus and renal dysfunction2016 | Third Faculty of Medicine
- Irbesartan in the treatment of arterial hypertension, diabetes and nephropathy2011 | First Faculty of Medicine, Third Faculty of Medicine
- Irbesartan in the treatment of arterial hypertension2000 | First Faculty of Medicine
- Irbesartan in patients with heart failure and preserved ejection fraction2008 | First Faculty of Medicine
- I-PRESERVE study. Irbesartan in chronic heart failure with preserved systolic function. How to treat diastolic heart failure2006 | First Faculty of Medicine
- Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis2023 | Publication without faculty affiliation
- Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial2023 | First Faculty of Medicine
- The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design2005 | First Faculty of Medicine
- The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design2005 | Faculty of Physical Education and Sport
- Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial2016 | Third Faculty of Medicine
- Sparsentan – nová možnost léčby pacientů s fokálně segmentální glomerulosklerózou?2023 | First Faculty of Medicine
- DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS2018 | First Faculty of Medicine